Outcomes of adjunctive eravacycline for severe and fulminant Clostridioides difficile infection
ERV may be useful as a potential adjunctive therapy for severe or fulminant CDI. Patients receiving ERV often were immunocompromised and had fulminant disease with critical illness. Future comparative studies are needed to evaluate the impact of adjunctive ERV for CDI.
Authors
- Rachel M. Kenney (ORCID: https://orcid.org/0000-0003-3696-2204)
- Michael P. Veve (ORCID: https://orcid.org/0000-0001-5967-5211)
- Susan L. Davis (ORCID: https://orcid.org/0000-0001-7521-9486)
- Mayur Ramesh (ORCID: https://orcid.org/0000-0002-1677-3994)
- Christen J Arena (ORCID: https://orcid.org/0009-0002-9787-358X)
Institutions
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
- Henry Ford Hospital (US)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1016/j.ijid.2024.107314
- Citations
- 2
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.78